trending Market Intelligence /marketintelligence/en/news-insights/trending/NL0b71yupGkFaJbAFRAZhA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

EMA committee requests additional data on Puma's breast cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

EMA committee requests additional data on Puma's breast cancer drug

The European Medicines Agency's Committee for Medicinal Products for Human Use issued its day-180 list of outstanding issues as part of its ongoing regulatory review of Puma Biotechnology Inc.'s breast cancer drug Nerlynx.

Puma is seeking marketing authorization for Nerlynx for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients who have previously been treated with Roche Holding AG's Herceptin.

The EMA committee requested additional data analyses related to the safety and efficacy of Nerlynx, also known as neratinib, and has instituted a clock stop in order to give the company time to respond to the list of issues.

Nerlynx received approval from the U.S. Food and Drug Administration for post-surgery treatment of adults with certain early-stage breast cancer after they have first been treated with Herceptin.

Puma expects the committee to issue an opinion regarding the marketing authorization application of the drug in the first quarter of 2018.

In addition, Puma said it has promoted Richard Bryce to the role of chief medical and scientific officer, effective Aug. 1. Bryce was previously senior vice president of clinical research and development at the company.